News | January 06, 2022
Aurobindo Pharma rolls out Molnaflu in India
The brand is now available pan-India through their distribution partner
The brand is now available pan-India through their distribution partner
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
It is the generic version of molnupiravir
It has also been granted permission to conduct trials for booster dose
The test kit is compatible with all standard Real-Time PCR machines with a test run time of 85 minutes. The result turnaround time, including sample collection and RNA extraction, is 130 minutes
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
Subscribe To Our Newsletter & Stay Updated
